Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is in a stable, monogamous sexual relationship with the same woman for at least 6 months and plans to maintain this relationship for the duration of the study~* history of premature ejaculation in the 6 months before study initiation not due to distress, interpersonal difficulty or medication withdrawal~* history of intravaginal ejaculatory latency time (IELT) of \< = 2 minutes in at least 3 out of 4 events~* blood pressure \< = 180/100 mmHg at screening and end of baseline~* patient and partner must agree to attempt sexual intercourse at minimum intervals specified in the protocol~* patient's partner must have a negative urine pregnancy test at time of screening~Exclusion Criteria:~* Not taken dapoxetine in a previous investigational drug study~* not using other forms of therapy for treatment of PE (behavioral therapy or medications applied to the skin)~* no history of any medical events that are associated with the development of PE~* not taken another investigational drug within 1 month~* no history of seizures or major psychiatric disorder such as depression or schizophrenia~* no alcohol abuse and dependence~* no known allergy or hypersensitivity to dapoxetine or other selective serotonin reuptake inhibitors (SSRIs)~* no partners with decreased interest in or painful intercourse or other forms of sexual dysfunction

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).